NTLA · Intellia Therapeutics
Conviction · Low · not more likely to lead the S&P 500 over the next three months
Note written ·
The last three months
Down 20.4% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.
Daily closes, to . Red: the note's price line under the older rule, a daily close above $12.00, set on 20 November 2026. The pale line is the 50-day average, $11.67 on .
Price line
A daily close above $12.00, back over the 50-day average, which would show the shares leading into the 10 March 2027 FDA decision; or an FDA approval of lonvo-z before that date.
A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.
Research onlyNot in the portfolio.
The business · as of
Intellia develops one-time CRISPR gene-editing treatments delivered inside the body: lonvo-z for hereditary angioedema and nex-z, with Regeneron, for transthyretin amyloidosis. It has no product sales yet. Revenue comes from collaborations: $7.2 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- In September 2026 the FDA accepted the lonvo-z application with Priority Review and set a 10 March 2027 action date, the company reported on 5 November 2026; it plans a US launch in the first quarter of 2027.
- What follows for the company
- General and administrative expense rose to $46.1 million in the third quarter of 2026 from $30.5 million a year earlier as the company built its field force; the net loss widened to $127.5 million.
- What follows for its customers, suppliers and competitors
- If approved, lonvo-z competes with Takeda (TAK), BioCryst (BCRX), Ionis (IONS) and KalVista (KALV) in HAE; Regeneron (REGN) shares nex-z economics, and its revenue to Intellia fell in the quarter.
What the price assumes · as of
At the 19 November 2026 close (filed inputs to 5 November 2026) the shares trade at EV/sales 17.7 and P/B 2.2, for an enterprise value of $936 million and a free-cash-flow yield of −26.8%. That holds only if lonvo-z wins approval and a launch revenue ramp starts to close a free cash outflow of $358 million over four quarters.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 20 November 2026 close
The last six quarters
- Revenue, latest quarter ($M)
- 7.2
- Revenue, change on a year (%)
- −48.0
- Operating margin (%)
- −1707.7
- Free cash flow, four quarters ($M)
- −358
- Net cash, cash less debt ($M)
- 400
- Enterprise value to sales (×)
- 19.0
- Free-cash-flow yield (%)
- −25.5
All filed numbers
What Intellia Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 7.2 | −48.0 | −1707.7 |
| first filed | 7.7 | −46.2 | −1472.3 |
| first filed | 15.0 | −9.5 | −668.1 |
| first filed | 23.0 | +78.8 | −428.9 |
| first filed | 13.8 | +51.3 | −808.9 |
| first filed | 14.2 | +104.8 | −772.2 |
| Pre-tax income ($M) | Not reported |
|---|---|
| Net income ($M) four quarters: −426 | −128 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +27.2 |
| Operating cash flow ($M) | −355 |
|---|---|
| Capital spending ($M) | 2.9 |
| Free cash flow ($M) | −358 |
| Cash and short-term investments ($M) | 474 |
|---|---|
| Debt ($M) long-term debt | 73.7 |
| Net cash, cash less debt ($M) | 400 |
| Deferred revenue ($M) −100.0% on a year | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 7.5 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 613 |
| Market value ($M) | 1,404 |
|---|---|
| Enterprise value, market value plus net debt ($M) | 1,003 |
| Enterprise value to sales (×) | 19.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.3 |
| Free-cash-flow yield (%) | −25.5 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 31.6% of shares outstanding sold short, 11.1 days of average trading to cover, −0.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
The thesis
Intellia Therapeutics is more likely to lag the S&P 500 over the next three months. Its main value event, the FDA decision on lonvo-z (lonvoguran ziclumeran) for hereditary angioedema (HAE), is due on 10 March 2027. That date falls just after the 63-session window. Until then the shares carry a cash burn of $358 million over four quarters and partner revenue that is shrinking. The rating is Low because the shares fell after good news. Positive lonvo-z data at the ACAAI meeting on 12 November 2026 were followed by a close of $9.70 on 13 November 2026, down from $10.55 the session before.
The drug looks strong on its own terms. The company's 5 November 2026 results release says the FDA accepted the Biologics License Application (BLA) in September with Priority Review and does not plan an advisory committee. It also says the company plans a US launch in the first quarter of 2027. The near-term problem is the gap between that approval and any revenue. In the meantime, the filed numbers show losses getting wider and the share count rising.
Bullish and bearish views on Intellia Therapeutics, Inc.
The bull case on Intellia Therapeutics, Inc. (NTLA), in brief: Priority Review, with no advisory panel planned. The bear case: partner revenue is falling fast.
Bull case
- Priority Review, with no advisory panel planned. The FDA set a target action date of 10 March 2027 and told the company it is not planning an advisory committee, according to the 5 November 2026 third-quarter release.
- Data that support a one-time treatment. Citizens reported on 13 November 2026 that two-thirds of patients in the ACAAI 2026 update were attack-free and 100% were free of long-term preventive therapy. The firm kept its $30 target and assigns $20 a share to the HAE opportunity.
- Funding reaches beyond the launch. The company reported $614.8 million in cash, equivalents and marketable securities at 30 September 2026. It says that funds operations at least into 2028, before lonvo-z revenue and before further draws on an OrbiMed term loan of up to $400 million signed in September 2026.
- Second Phase 3 program fully enrolled. MAGNITUDE-2, which tests nex-z (nexiguran ziclumeran) in hereditary transthyretin amyloidosis with polyneuropathy, finished enrolling in the third quarter of 2026 with more than the targeted 60 patients, per the 5 November 2026 release.
Bear case
- Partner revenue is falling fast. Collaboration revenue was $7.2 million in the quarter to 30 September 2026, down 48.0% from a year earlier. The company attributes the drop mainly to lower revenue from Regeneron.
- Losses widen as launch costs build. The third-quarter net loss was $127.5 million, against $101.3 million a year earlier. General and administrative expense rose to $46.1 million from $30.5 million, while research spending fell to $83.3 million from $94.7 million (5 November 2026 release).
- Dilution and new debt. Diluted shares rose 27.2% from a year earlier in the quarter to 30 September 2026. The 10-Q filed 5 November 2026 shows $74 million of long-term debt.
- Most analysts are cautious. BofA Securities kept a Hold rating on 14 November 2026. JPMorgan raised its target to $9 from $8 on 9 November 2026, which is below the 19 November 2026 close of $9.52.
- Planned insider selling continues. SEC Form 4 filings show the chief executive sold 9,000 shares at $11.99 on 2 November 2026 and 22,675 shares at an average of $12.65 on 20 August 2026 and 21 August 2026, all under a Rule 10b5-1 plan.
Price setup · as of
Intellia closed at $9.52 on 19 November 2026. That is 48.5% below the 52-week intraday high of $18.48 set on 2 July 2026. On adjusted daily closes, the shares sit below the 50-day average of $11.70 and the 200-day average of $12.89, and they are down 25.9% over three months from a reference close of $12.84 on 21 August 2026.
The latest fall came after good news. The shares closed at $10.55 on 12 November 2026, the day of the ACAAI data and the investor webcast, then fell to $9.70 on 13 November 2026. They have stayed between $9.52 and $9.86 since. The 52-week closing low is $8.04 from 20 November 2025.
A common market view is that biotech shares drift lower before an FDA decision and then rally into it. Across US stocks, no reliable effect has been found so far after one-day drops of this kind. The case therefore rests on the calendar and on the cash figures.
Catalysts ahead
- 7 December 2026: Intellia at the 23rd Global Cardiovascular Clinical Trialists Forum, Washington, D.C. (7 December to 9 December 2026). Any update on the timing of the nex-z Phase 3 trial in cardiomyopathy would change how much value sits beyond lonvo-z.
- ~26 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows the year-end cash, the term-loan draws and the 2027 spending plan going into launch.
- 10 March 2027: FDA target action date for lonvo-z in hereditary angioedema. Approval and the approved label decide whether the planned first-quarter 2027 launch happens; this is the event the case turns on.
What it trades with · as of
The shares trade on events: the FDA date, data presentations and launch news. Partner economics matter too, because Regeneron (REGN) co-develops nex-z and was the main source of the revenue decline. In HAE, lonvo-z would compete with preventive treatments from Takeda (TAK), BioCryst (BCRX) and Ionis (IONS) and with KalVista's (KALV) on-demand therapy. In transthyretin amyloidosis, nex-z would face Alnylam (ALNY), BridgeBio (BBIO) and Pfizer (PFE). How investors price gene-editing companies in general also moves the shares.
Caveats
- Intellia reports no product revenue; all revenue is from collaborations, so quarterly revenue reflects partner accounting rather than demand. Form 10-Q for the third quarter of 2026 · as of
- The company has a secured term loan facility of up to $400 million with OrbiMed, and diluted shares rose 27.2% from a year earlier in the third quarter of 2026. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
- The FDA accepted the lonvo-z Biologics License Application with Priority Review and a target action date of 10 March 2027, and is not currently planning an advisory committee. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Collaboration revenue was $7.2 million in the third quarter of 2026, against $13.8 million a year earlier, mainly because of lower Regeneron revenue. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
- The third-quarter 2026 net loss was $127.5 million, against $101.3 million a year earlier; general and administrative expense rose to $46.1 million from $30.5 million. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Cash, equivalents and marketable securities were $614.8 million at 30 September 2026, which the company says funds operations at least into 2028. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
- In September 2026 Intellia signed a senior secured term loan facility of up to $400 million with OrbiMed. Intellia third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Citizens kept a Market Outperform rating and a $30 target after the ACAAI lonvo-z data, citing two-thirds of patients attack-free. Investing.com, Citizens note report · as of
- JPMorgan raised its Intellia price target to $9 from $8. CNN Markets analyst summary · as of
- The chief executive sold 9,000 shares at $11.99 on 2 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 3 November 2026 · as of
Sources
- Intellia Therapeutics, Inc. - Form 8-K - FY2026 · sec.gov ·
- Intellia stock price target maintained at $30 by Citizens on HAE data · za.investing.com ·
- NTLA Stock Quote Price and Forecast · cnn.com
- Intellia Therapeutics Reports Q3 2026 Results, $615M Cash and $127.5M Net Loss · tradingview.com
Related · shared themes
SVRA
Savara
Savara's shares are modestly more likely to beat the S&P 500 over three months as its lung drug Molbreevi nears the FDA's 22 November 2026…
ZVRA
Zevra Therapeutics
Zevra Therapeutics is more likely to lag the S&P 500 over three months after Europe's drug committee gave a final negative opinion on…
LRMR
Larimar Therapeutics
Larimar Therapeutics is modestly more likely than not to lead the S&P 500 over three months: its nomlabofusp filing is complete and eight…
RZLT
Rezolute
Rezolute's ersodetug met the primary endpoint of its Phase 3 upLIFT study (13 responders of 16 against nine needed) and a $100 million…